SCHEMBL6101129

SCHEMBL6101129

COc1cc(CC(=O)Nc2cccc(-c3cccc(Oc4ccccc4)c3)c2)ccc1OCCN

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.57
LMNA P02545 4/20 0.57
NPSR1 Q6W5P4 4/20 0.57
HSD17B10 Q99714 4/20 0.57
HTT P42858 3/20 0.57
KMT2A Q03164 3/20 0.57
TSHR P16473 3/20 0.57
MAPK1 P28482 3/20 0.57
ALDH1A1 P00352 3/20 0.57
MAPT P10636 3/20 0.57
MEN1 O00255 2/20 0.57
STAT3 P40763 2/20 0.51
TP53 P04637 2/20 0.51
HPGD P15428 2/20 0.51
XBP1 P17861 1/20 0.51
HTR1E P28566 1/20 0.51
NTSR1 P30989 1/20 0.51
STAT1 P42224 1/20 0.51
S1PR3 Q99500 1/20 0.51
FBP1 P09467 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6101654 0.92 SMN1; SMN2 (0.63) SMN1; SMN2LMNANPSR1HSD17B10HTT
Hydrochloric Acid SCHEMBL6099402 0.91 SMN1; SMN2 (0.62) SMN1; SMN2LMNANPSR1HSD17B10HTT
SCHEMBL6100605 0.91 SMN1; SMN2 (0.62) SMN1; SMN2LMNANPSR1HSD17B10HTT
SCHEMBL6100336 0.88 SMN1; SMN2 (0.60) SMN1; SMN2LMNANPSR1HSD17B10HTT
SCHEMBL6102257 0.87 SMN1; SMN2 (0.53) SMN1; SMN2LMNANPSR1HSD17B10HTT
SCHEMBL6099956 0.86 SMN1; SMN2 (0.55) SMN1; SMN2LMNANPSR1HSD17B10HTT
SCHEMBL6102037 0.86 FBP1 (0.67) SMN1; SMN2LMNANPSR1HSD17B10HTT
SCHEMBL6100822 0.85 SMN1; SMN2 (0.57) SMN1; SMN2LMNANPSR1HSD17B10HTT
SCHEMBL6100236 0.85 SMN1; SMN2 (0.54) SMN1; SMN2LMNANPSR1HSD17B10HTT
SCHEMBL6099640 0.85 BCL9 (0.58) SMN1; SMN2LMNANPSR1HSD17B10HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084176-B2 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2006-08-01 US claimed
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-09 US claimed
EP-1403235-A1 N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Dainippon Pharmaceutical Co., Ltd. (JP) 2004-03-31 EP claimed
US-7084176-B2 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2006-08-01 US disclosed
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-09 US disclosed
EP-1403235-A1 N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Dainippon Pharmaceutical Co., Ltd. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same HRH2, CCR8, CYP2C8 SMN1; SMN2 2474/4885LMNA 3086/4885NPSR1 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.